Help
RSS
API
Feed
Maltego
Contact
Domain > www.lexiscan.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2015-04-29
191.238.8.26
(
ClassC
)
2024-10-21
40.121.8.241
(
ClassC
)
Port 443
HTTP/1.1 200 OKContent-Length: 55864Content-Type: text/html; charsetutf-8Date: Mon, 21 Oct 2024 16:41:47 GMTServer: Microsoft-IIS/10.0Cache-Control: privateSet-Cookie: ARRAffinityccaf055fd1d84a43121b3f98a62b3ed0a4a8fa41d2e6f072230136cc936ff633;Path/;HttpOnly;Secure;Domainwww.lexiscan.comSet-Cookie: ARRAffinitySameSiteccaf055fd1d84a43121b3f98a62b3ed0a4a8fa41d2e6f072230136cc936ff633;Path/;HttpOnly;SameSiteNone;Secure;Domainwww.lexiscan.comX-AspNetMvc-Version: 5.2X-AspNet-Version: 4.0.30319X-Powered-By: ASP.NETX-Frame-Options: SAMEORIGIN !DOCTYPE html>html>head> !-- OneTrust Cookies Consent Notice start for lexiscan.com --> script typetext/javascript srchttps://cdn.cookielaw.org/consent/01918e8e-d04f-7c48-ac2c-419f83313056/OtAutoBlock.js >/script> script srchttps://cdn.cookielaw.org/scripttemplates/otSDKStub.js typetext/javascript charsetUTF-8 data-domain-script01918e8e-d04f-7c48-ac2c-419f83313056 >/script> script typetext/javascript> function OptanonWrapper() { } /script> !-- OneTrust Cookies Consent Notice end for lexiscan.com --> meta charsetutf-8 /> meta nameviewport contentwidthdevice-width, initial-scale1.0, maximum-scale1.0, user-scalable0> title>Official Home Page | Lexiscan® (regadenoson) injection/title> meta namedescription contentAccess information about Lexiscan® (regadenoson) injection for pharmacologic stress testing. Please see full Prescribing Information for Lexiscan. /> meta namekeywords content /> !-- Schema --> script typeapplication/ld+json> { @context: https://schema.org, @type: MedicalWebPage, name: Lexiscan® (regadenoson) injection, description: Access information about Lexiscan®; (regadenoson) injection for pharmacologic stress testing. Please see full Prescribing Information for Lexiscan., audience: https://schema.org/Patient, significantLink: https://www.lexiscan.com/ClinicalAttributes/ClinicalPharmacology, https://www.lexiscan.com/OperationalFlexibility/Dosing, https://www.lexiscan.com/OperationalFlexibility/Considerations , mainEntity: { @type: Drug, @id: MedicalWebPage/mainEntity:Drug , name: Lexiscan, alternateName: Lexiscan®, mainEntityOfPage: https://www.lexiscan.com/, activeIngredient: regadenoson, sameAs: https://en.wikipedia.org/wiki/Regadenoson, warning: Fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest have occurred following Lexiscan injection., Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to Lexiscan. }, about: { @type: MedicalCondition, name: myocardial perfusion imaging, sameAs: https://en.wikipedia.org/wiki/Myocardial_perfusion_imaging, @id: MedicalWebPage/about:MedicalCondition, possibleTreatment: { @type: MedicalTherapy, description: Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress., drug: { @id: MedicalWebPage/mainEntity:Drug } }, associatedAnatomy: { @type: AnatomicalSystem, name:heart } } } /script> !-- Google Tag Manager --> script> (function (w, d, s, l, i) { wl wl || ; wl.push({ gtm.start: new Date().getTime(), event: gtm.js }); var f d.getElementsByTagName(s)0, j d.createElement(s), dl l ! dataLayer ? &l + l : ; j.async true; j.src https://www.googletagmanager.com/gtm.js?id + i + dl; f.parentNode.insertBefore(j, f); })(window, document, script, dataLayer, GTM-WN54VX);/script> !-- End Google Tag Manager --> !-- link relstylesheet hrefhttps://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css integritysha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm crossoriginanonymous> script srchttps://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js integritysha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl crossoriginanonymous>/script> --> link hrefhttps://fonts.googleapis.com/css?familyOpen+Sans:400,400i,700,700i relstylesheet> link href//amp.azure.net/libs/amp/latest/skins/amp-default/azuremediaplayer.min.css relstylesheet> script src//amp.azure.net/libs/amp/latest/azuremediaplayer.min.js>/script> script srchttps://cdn.bitmovin.com/player/web/8/bitmovinplayer.js typetext/javascript>/script> link href/Content/css?vcToFgjOe2Vrh76VN4Hp3wXXIRmWH8wd4_Rdsm4d59eM1 relstylesheet/> script src/bundles/modernizr?vinCVuEFe6J4Q07A0AcRsbJic_UE5MwpRMNGcOtk94TE1>/script>/head>body classpage-home data-section data-page> !-- Google Tag Manager (noscript) --> noscript> iframe srchttps://www.googletagmanager.com/ns.html?idGTM-WN54VX height0 width0 styledisplay:none;visibility:hidden>/iframe> /noscript> !-- End Google Tag Manager (noscript) --> div classoverlay-wrapper overlay-wrapper--interstitial container-fluid> div classoverlay overlay--interstitial> div classrow> div classcol-xs-12> div classtitle>You Are Now Leaving Lexiscan.com/HCP/div> p>The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site./p> div classcontent>/div> /div> /div> div classrow button-wrapper> div classcol-xs-6 stay> a classbutton cancel hrefjavascript:void(0)>Stay on This Page/a> /div> div classcol-xs-6 leave> a classbutton leave hrefjavascript:void(0)>Leave This Page/a> /div> /div> /div>/div>div idroadblock classoverlay-wrapper overlay-wrapper--roadblock container-fluid> div classoverlay overlay--confirm overlay--confirm--patient> div classoverlay--confirm-inner container> a classclose hrefjavascript:void(0)>X/a> p>You are about to leave Lexiscan.com and redirect to Lexiscaninfo.com./p> div classrow button-wrapper> div classcol-12 col-sm-4> a classbutton--primary patient cancel-patient hrefjavascript:void(0)>Cancel/a> /div> div classcol-12 col-sm-4> a classbutton--primary patient ok-patient hrefhttps://www.lexiscaninfo.com target_blank>OK/a> /div> /div> /div> /div> div classoverlay overlay--confirm overlay--confirm--hcp> div classoverlay--confirm-inner container> a classclose hrefjavascript:void(0)>X/a> p>The information contained on this site is intended for healthcare professionals in the United States only./p> p>Please verify that you are a US healthcare professional./p> div classrow button-wrapper> div classcol-12 col-sm-4> a classbutton--primary cancel-hcp hcp hrefhttps://www.lexiscaninfo.com/lexiscan/index.html>No, I am not/a> /div> div classcol-12 col-sm-4> a classbutton--primary hcp ok-hcp hrefjavascript:void(0)>Yes, I am/a> /div> /div> /div> /div> div classoverlay overlay--roadblock> div classrow bg-gray> div classcol-12> div classcontainer> div classrow> div classcol-12 col-sm-6> div classdisclaimer>This information is intended for US healthcare professionals only./div> /div> div classcol-12 col-sm-6> div classpi-link>a hrefhttps://www.astellas.us/docs/lexiscan.pdf target_blank>Prescribing Information span classicon icon--download>/span>/a>/div> /div> /div> /div> /div> /div> div classrow> div classcol-12> div classcontainer> div classrow> div classcol-12 text-center> img classlogo src/Content/img/logo--lexiscan.png altLexiscan logo /> /div> /div> div classrow> div classcol-12> h3>Choose the first standard-dose, ready-to-use pharmacologic stress br />agent in a prefilled syringesup>1,a/sup>/h3> /div> /div> div classrow> div classcol-12 col-sm-8 offset-sm-2> p classfootnote-single>sup>a/sup>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Lexiscan if it contains particulate matter or is discolored./p> /div> /div> section> div classcontainer> div classrow> div classcol-12> div classreferences1 accordion reference-roadblock-textalign data-allow-toggletrue> p aria-expandedfalse aria-controlsreferences-10 classaccordion-trigger references-roadblock-p overlay1>Reference/p> ol roleregion idreferences-10 aria-hiddentrue classaccordion-panel1 hidden> li>Lexiscan package insert. Northbrook, IL: Astellas Pharma US, Inc./li> /ol> /div> /div> /div> /div> /section> div classrow button-wrapper stylemargin-top:unset> div classcol-12 col-sm-4 hcp> a classbutton--primary hcp hrefjavascript:void(0)>I am a US healthcare professional/a> /div> div classcol-12 col-sm-4 patient> a classbutton--primary patient hrefhttps://www.lexiscaninfo.com/lexiscan/index.html>I am a patient/a> /div> /div> div classisi-content text-left> div idisi-top--roadblock classfull-isi clearfix> div classcontainer> div classrow> div classcol col-md-12>h4>INDICATION AND IMPORTANT SAFETY INFORMATION/h4>h4>Indication/h4>p>Lexiscanspan classgeneric>sup>®/sup> (regadenoson) injection/span> is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress./p>h4>IMPORTANT SAFETY INFORMATION/h4>h4 classno-padding--bottom>Contraindications/h4>p>Do not administer Lexiscan to patients with second- or third-degree AV block or sinus node dysfunction unless these patients have a functioning artificial pacemaker./p>h4 classno-padding--bottom>Warnings and Precautions/h4>p>strong>Myocardial Ischemia/strong>br />Fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest have occurred following Lexiscan injection. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to Lexiscan. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan. Adhere to the recommended duration of injection. As noted in an animal study, longer injection times may increase the duration and magnitude of increase in coronary blood flow. If serious reactions to Lexiscan occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by Lexiscan./p>p>strong>Sinoatrial and Atrioventricular Nodal Block/strong> br />Adenosine receptor agonists, including Lexiscan, can depress the SA and AV nodes and may cause first-, second-, or third-degree AV block, or sinus bradycardia requiring intervention. In postmarketing experience, heart block (including third degree), and asystole within minutes of Lexiscan administration have occurred./p>p>strong>Atrial Fibrillation/Atrial Flutter/strong>br />New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported following Lexiscan injection./p>p>strong>Hypersensitivity, Including Anaphylaxis/strong> br />Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred. In clinical trials, hypersensitivity reactions were reported in fewer than 1 percent of patients./p>p>strong>Hypotension/strong>br />Adenosine receptor agonists, including Lexiscan, induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. In postmarketing experience, transient ischemic attacks, seizures and syncope have been observed./p>p>strong>Hypertension/strong>br />Adenosine receptor agonists, including Lexiscan, may result in clinically significant increases in blood pressure in some patients. In postmarketing experience, cases of potentially clinically significant hypertension have been reported, particularly in patients with underlying hypertension and when low-level exercise was included in the MPI./p>p>strong>Bronchoconstriction/strong>br />Adenosine receptor agonists, including Lexiscan, may cause dyspnea, bronchoconstriction and respiratory compromise. Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following Lexiscan administration./p>p>strong>Seizure/strong>br />Lexiscan may lower the seizure threshold; obtain a seizure history. New-onset or recurrence of convulsive seizures has occurred following Lexiscan injection. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with Lexiscan injection. Methylxanthine use is not recommended in patients who experience a seizure in association with Lexiscan administration./p>p>strong>Cerebrovascular Accident (Stroke)/strong>br />Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of Lexiscan including hypotension or hypertension may be associated with these adverse reactions./p>h4 classno-padding--bottom>Adverse Reactions/h4>p>In clinical trials, the most common adverse reactions (≥5%) to Lexiscan were dyspnea, headache, flushing, chest discomfort, angina pectoris or ST-segment depression, dizziness, chest pain, nausea, abdominal discomfort, dysgeusia, and feeling hot. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache, which resolved in most patients within 30 minutes. Aminophylline was used as a reversal agent in 3% of patients./p>p>In postmarketing experience, the following additional adverse reactions have occurred: supraventricular tachyarrhythmias, acute coronary syndrome (ACS), tremor, QTc prolongation, abdominal pain in association with nausea, vomiting, or myalgias, diarrhea, fecal incontinence, wheezing and musculoskeletal pain./p> /div> /div> /div> /div> /div> /div> /div> /div> /div> div classfooter-content> div classcontainer>footer> div classcol-12 col-sm-8 footer-nav footer-nav-new mobile-101> ul stylemargin-left: 24px;> li>a hrefhttps://www.astellas.us/about/index.aspx target_blank>About Astellas/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.com/us/privacy-policy target_blank>Privacy Policy/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/footer/legal/ target_blank>Terms of Use/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/about/contact/index.aspx target_blank>Contact Us/a>/li> /ul> /div> div classcol-12 col-sm-8 footer-nav footer-nav-new mobile-100> ul> li>a hrefhttps://www.astellas.us/about/index.aspx target_blank>About Astellas/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.com/us/privacy-policy target_blank>Privacy Policy/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/footer/legal/ target_blank>Terms of Use/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/about/contact/index.aspx target_blank>Contact Us/a>/li> /ul> /div> div classcol-12 col-sm-4 text-center> div classfooter-logo mobile-101 stylepadding-left: 100px;> img src/Content/img/logo--astellas--white.png altAstellas logo /> /div> div classfooter-logo mobile-100> img src/Content/img/logo--astellas--white.png altAstellas logo /> /div> /div> div classcol-12 col-sm-8 offset-sm-4 disclaimers mobile-101 foot-s st-1> p>All trademarks are the property of their respective owners. /p> p> Copyright © 2024 Astellas Pharma Inc. or its affiliates.span classmobile-break> /span>MAT-US-LEX-2023-00001 12/23 /p> p> MAT-US-LEX-2024-00005 07/24 /p> /div> div classcol-12 col-sm-8 offset-sm-4 disclaimers foot-s mobile-100 foot-align> p>All trademarks are the property of their respective owners. /p> p> Copyright © 2024 Astellas Pharma Inc. or its affiliates. /p> p> MAT-US-LEX-2023-00001 12/23 /p> p> MAT-US-LEX-2024-00005 07/24 /p> /div>/footer> /div> /div>/div>div classoverlay-wrapper overlay-wrapper--image container-fluid> div classoverlay overlay--image> div classcancel text-right>X/div> div classpreview-image> /div> /div>/div>div classoverlay-wrapper overlay-wrapper--share container-fluid> div classoverlay overlay--share> div classclose text-right>X/div> p classtitle>Copy the link to share this resource/p> input typetext namelink classlink-to-copy /> button classbutton button--copy>Copy link/button> /div>/div> div classheader-content>header classnav-down> div classrow bg-gray> div classcontainer> div classrow header-top> div classdisclaimer d-none d-sm-block>This information is intended for US healthcare professionals only./div> div classisi-link>a href#isi-top>Important Safety Information span classicon icon--arrow--down>/span>/a>/div> div classpi-link>a hrefhttps://www.astellas.us/docs/lexiscan.pdf target_blank>Prescribing Information span classicon icon--download>/span>/a>/div> div classpatient-link d-none d-sm-flex>a hrefhttps://www.lexiscaninfo.com/lexiscan/index.html target_blank>Patient Website span classicon icon--external-link--gray>/span>/a>/div> /div> /div> /div> div classrow d-sm-none> div classdisclaimer>This information is intended for US healthcare professionals only./div> /div> div classrow row--nav> div classlogo logo--header> a href/>img src/Content/img/logo--lexiscan.png altLexiscan logo />/a> /div> nav classnavbar navbar-expand-sm> div classnavbar-header> button typebutton classnavbar-toggler data-togglecollapse data-target.navbar-collapse> span classicon-bar>/span> span classicon-bar>/span> span classicon-bar>/span> span classtitle>Menu/span> /button> /div> div classoverlay-wrapper overlay-wrapper--background> div classnavbar-collapse collapse> ul classnav navbar-nav> li classmenu-close d-sm-none>a hrefjavascript:void(0)>X/a>/li> li classd-sm-none home>a href/>Home/a>/li> li classclosed dropdown dropdown--clinical-attributes> a>Clinical Attributes/a> ul classsub-menu> li classclinical-pharmacology>a href/ClinicalAttributes/ClinicalPharmacology>Clinical Pharmacology/a>/li> li classclosed> a href/ClinicalAttributes/ClinicalData>Clinical Data/a> ul classsub-menu> li classadvance-mpi>a href/ClinicalAttributes/AdvanceMPI>Pivotal Trials/a>/li> li classexerrt> a href/ClinicalAttributes/EXERRT>Inadequatebr />Exercise Stress/a> /li> li classasthma-copd>a href/ClinicalAttributes/AsthmaCOPD>Asthma/COPD/a>/li> li classrenal-impairment>a href/ClinicalAttributes/RenalImpairment>Renal Impairment/a>/li> /ul> /li> /ul> /li> li classclosed dropdown dropdown--operational-flexibility> a>Operational Information/a> ul classsub-menu> li classdosing>a href/OperationalFlexibility/Dosing>Administration Protocols/a>/li> li classpharmacy-considerations>a href/OperationalFlexibility/Considerations>Pharmacy Considerations/a>/li> li classpatient-prep>a href/OperationalFlexibility/PatientPrep>Patient Preparation/a>/li> /ul> /li> li classclosed dropdown dropdown--resources> a>Resources/a> ul classsub-menu> li classpatient-resources>a href/Resources/PatientResources>Patient Resources/a>/li> li classpractice-resources>a href/Resources/PracticeResources>Practice Resources/a>/li> li classpublications>a href/Resources/Publications>Publications/a>/li> /ul> /li> li classbtn-code-bill>a hrefhttps://www.astellaspharmasupportsolutions.com/products/lexiscan/index.aspx target_blank> Coding and Billing /a>/li> li classrequest-rep btn-purple>a href/RequestRep>Request Information/a> /li> /ul> /div> /div> /nav> /div> div classrow row--subnav row--subnav--tertiary> ul classsubnav--clinical-attributes tertiary> li classadvance-mpi>a classadvance-mpi href/ClinicalAttributes/AdvanceMPI>Pivotal Trials/a>/li> li classexerrt>a classexerrt href/ClinicalAttributes/EXERRT>Inadequate Exercise Stress/a>/li> li classasthma-copd>a classasthma-copd href/ClinicalAttributes/AsthmaCOPD>Asthma/ COPD/a>/li> li classrenal-impairment>a classrenal-impairment href/ClinicalAttributes/RenalImpairment>Renal Impairment/a>/li> /ul> /div>/header> /div> div classbody-content> link relstylesheet/reload typetext/css href/Content/dist/main.css>section classbg-gradient> div classcontainer> div classrow> div classcol-12> div classjumbotron transparent> div classrow heart-animation> div classcol-12 col-sm-4 stylepadding-top:20px;> h1 classanimated-h1-mb>Choose the first standard-dose, ready-to-use pharmacologic stress agent in a prefilled syringesup>1,a/sup>/h1> ul idlistAnim classlistAnim-ul mob-animate-li-mb> li classanimated-h-mb animated-first-child-no-bullet>Pharmacy Considerations:/li> li>NO weight-based calculations/li> li>NO vial draw-up needed/li> li>NO pump required/li> /ul> div classd-block d-sm-none> p>With clinical experience and offering operational flexibility, Lexiscansup>®/sup> (regadenoson) injection is an important choice in the nuclear cardiology community./p> p>Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress./p> /div> p classfootnote footnote-mt-animated-List>sup classoffset>a/sup>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Lexiscan if it contains particulate matter or is discolored./p> div classreferences accordion data-allow-toggletrue> p aria-expandedfalse aria-controlsreferences-3 classaccordion-trigger accordion-trigger--single>Reference/p> ol roleregion idreferences-3 aria-hiddentrue classaccordion-panel hidden> li>Lexiscan package insert. Northbrook, IL: Astellas Pharma US, Inc./li> /ol> /div> /div> div classd-none d-sm-block col-sm-4 align-bottom> !-- We are using a background image for the animation --> !--img src/Content/img/home-heart.png />--> !--p classfootnote>Image is an artistic representation of coronary arteries. No depiction of action or function of Lexiscan is intended or implied./p>--> /div> div classd-none d-sm-block col-sm-4 stylepadding-top: 20px;> p>With clinical experience and offering operational flexibility, Lexiscansup>®/sup> (regadenoson) injection is an important choice in the nuclear cardiology community./p> p>Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress./p> /div> /div> div classrow d-none d-sm-block> div classcol-4 offset-4> p classfootnote>Image is an artistic representation of coronary arteries. No depiction of action or function of Lexiscan is intended or implied./p> /div> /div> div classrow row--callouts> div classcol> div classcallout-wrapper nowrap row no-gutters> div classcallout callout--three-column callout--value no-border> div classtitle>Resources for Your Practice/div> p>Find informative materials to use in your practice or share with colleagues./p> div classlink> a href/Resources/PracticeResources>Access practice resources/a> /div> /div> div classcallout callout--three-column callout--value no-border> div classtitle>Mechanism of Action (MOA)/div> p> See how Lexiscan induces coronary vasodilation at the molecular level. /p> div classlink> a href/ClinicalAttributes/ClinicalPharmacology>Learn more about the MOA/a> /div> /div> div classcallout callout--three-column callout--value no-border> div classtitle>Dosing and Administration/div> p>Explore how Lexiscan dosing and administration can be integrated into existing operational workflows./p> div classlink> a href/OperationalFlexibility/Dosing>Learn more about dosing/a> /div> /div> /div> /div> /div> /div> /div> /div> /div>/section>section> div classcontainer> div classrow> div classsignpost-wrapper signpost-wrapper--single> div classsignpost signpost--next single>span>Next Section: /span>a href/ClinicalAttributes/ClinicalPharmacology>Clinical Pharmacology/a>/div> /div> /div> /div>/section> /div> div classisi-content> div idisi-top-anchor classfull-isi>/div> div idisi-top classfull-isi clearfix> div classcontainer> div classrow> div classcol col-md-12>h4>INDICATION AND IMPORTANT SAFETY INFORMATION/h4>h4>Indication/h4>p>Lexiscanspan classgeneric>sup>®/sup> (regadenoson) injection/span> is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress./p>h4>IMPORTANT SAFETY INFORMATION/h4>h4 classno-padding--bottom>Contraindications/h4>p>Do not administer Lexiscan to patients with second- or third-degree AV block or sinus node dysfunction unless these patients have a functioning artificial pacemaker./p>h4 classno-padding--bottom>Warnings and Precautions/h4>p>strong>Myocardial Ischemia/strong>br />Fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest have occurred following Lexiscan injection. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to Lexiscan. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan. Adhere to the recommended duration of injection. As noted in an animal study, longer injection times may increase the duration and magnitude of increase in coronary blood flow. If serious reactions to Lexiscan occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by Lexiscan./p>p>strong>Sinoatrial and Atrioventricular Nodal Block/strong> br />Adenosine receptor agonists, including Lexiscan, can depress the SA and AV nodes and may cause first-, second-, or third-degree AV block, or sinus bradycardia requiring intervention. In postmarketing experience, heart block (including third degree), and asystole within minutes of Lexiscan administration have occurred./p>p>strong>Atrial Fibrillation/Atrial Flutter/strong>br />New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported following Lexiscan injection./p>p>strong>Hypersensitivity, Including Anaphylaxis/strong> br />Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred. In clinical trials, hypersensitivity reactions were reported in fewer than 1 percent of patients./p>p>strong>Hypotension/strong>br />Adenosine receptor agonists, including Lexiscan, induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. In postmarketing experience, transient ischemic attacks, seizures and syncope have been observed./p>p>strong>Hypertension/strong>br />Adenosine receptor agonists, including Lexiscan, may result in clinically significant increases in blood pressure in some patients. In postmarketing experience, cases of potentially clinically significant hypertension have been reported, particularly in patients with underlying hypertension and when low-level exercise was included in the MPI./p>p>strong>Bronchoconstriction/strong>br />Adenosine receptor agonists, including Lexiscan, may cause dyspnea, bronchoconstriction and respiratory compromise. Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following Lexiscan administration./p>p>strong>Seizure/strong>br />Lexiscan may lower the seizure threshold; obtain a seizure history. New-onset or recurrence of convulsive seizures has occurred following Lexiscan injection. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with Lexiscan injection. Methylxanthine use is not recommended in patients who experience a seizure in association with Lexiscan administration./p>p>strong>Cerebrovascular Accident (Stroke)/strong>br />Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of Lexiscan including hypotension or hypertension may be associated with these adverse reactions./p>h4 classno-padding--bottom>Adverse Reactions/h4>p>In clinical trials, the most common adverse reactions (≥5%) to Lexiscan were dyspnea, headache, flushing, chest discomfort, angina pectoris or ST-segment depression, dizziness, chest pain, nausea, abdominal discomfort, dysgeusia, and feeling hot. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache, which resolved in most patients within 30 minutes. Aminophylline was used as a reversal agent in 3% of patients./p>p>In postmarketing experience, the following additional adverse reactions have occurred: supraventricular tachyarrhythmias, acute coronary syndrome (ACS), tremor, QTc prolongation, abdominal pain in association with nausea, vomiting, or myalgias, diarrhea, fecal incontinence, wheezing and musculoskeletal pain./p> /div> /div> /div> /div> div classisi isi-mobile-top-link sticky-isi-main collapsed> div classsticky-isi-mobile> div classbg-gray> div classcontainer> div classrow> div classcol-12> h4 classisi-expand sticky-isi>IMPORTANT SAFETY INFORMATION AND INDICATION/h4> /div> /div> /div> /div> div classcontainer> div classrow no-gutters row--sticky-isi> div classcol-12>h4>IMPORTANT SAFETY INFORMATION/h4>h4 classno-padding--bottom>Contraindications/h4>p>Do not administer Lexiscan to patients with second- or third-degree AV block or sinus node dysfunction unless these patients have a functioning artificial pacemaker./p>h4 classno-padding--bottom>Warnings and Precautions/h4>p>strong>Myocardial Ischemia/strong>br />Fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest have occurred following Lexiscan injection. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to Lexiscan. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan. Adhere to the recommended duration of injection. As noted in an animal study, longer injection times may increase the duration and magnitude of increase in coronary blood flow. If serious reactions to Lexiscan occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by Lexiscan./p>p>strong>Sinoatrial and Atrioventricular Nodal Block/strong> br />Adenosine receptor agonists, including Lexiscan, can depress the SA and AV nodes and may cause first-, second-, or third-degree AV block, or sinus bradycardia requiring intervention. In postmarketing experience, heart block (including third degree), and asystole within minutes of Lexiscan administration have occurred./p>p>strong>Atrial Fibrillation/Atrial Flutter/strong>br />New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported following Lexiscan injection./p>p>strong>Hypersensitivity, Including Anaphylaxis/strong> br />Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred. In clinical trials, hypersensitivity reactions were reported in fewer than 1 percent of patients./p>p>strong>Hypotension/strong>br />Adenosine receptor agonists, including Lexiscan, induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. In postmarketing experience, transient ischemic attacks, seizures and syncope have been observed./p>p>strong>Hypertension/strong>br />Adenosine receptor agonists, including Lexiscan, may result in clinically significant increases in blood pressure in some patients. In postmarketing experience, cases of potentially clinically significant hypertension have been reported, particularly in patients with underlying hypertension and when low-level exercise was included in the MPI./p>p>strong>Bronchoconstriction/strong>br />Adenosine receptor agonists, including Lexiscan, may cause dyspnea, bronchoconstriction and respiratory compromise. Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following Lexiscan administration./p>p>strong>Seizure/strong>br />Lexiscan may lower the seizure threshold; obtain a seizure history. New-onset or recurrence of convulsive seizures has occurred following Lexiscan injection. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with Lexiscan injection. Methylxanthine use is not recommended in patients who experience a seizure in association with Lexiscan administration./p>p>strong>Cerebrovascular Accident (Stroke)/strong>br />Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of Lexiscan including hypotension or hypertension may be associated with these adverse reactions./p>h4 classno-padding--bottom>Adverse Reactions/h4>p>In clinical trials, the most common adverse reactions (≥5%) to Lexiscan were dyspnea, headache, flushing, chest discomfort, angina pectoris or ST-segment depression, dizziness, chest pain, nausea, abdominal discomfort, dysgeusia, and feeling hot. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache, which resolved in most patients within 30 minutes. Aminophylline was used as a reversal agent in 3% of patients./p>p>In postmarketing experience, the following additional adverse reactions have occurred: supraventricular tachyarrhythmias, acute coronary syndrome (ACS), tremor, QTc prolongation, abdominal pain in association with nausea, vomiting, or myalgias, diarrhea, fecal incontinence, wheezing and musculoskeletal pain./p>h4>Indication/h4>p>Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress./p> /div> /div> /div> /div> /div> /div> div classfooter-content> div classcontainer>footer> div classcol-12 col-sm-8 footer-nav footer-nav-new mobile-101> ul stylemargin-left: 24px;> li>a hrefhttps://www.astellas.us/about/index.aspx target_blank>About Astellas/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.com/us/privacy-policy target_blank>Privacy Policy/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/footer/legal/ target_blank>Terms of Use/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/about/contact/index.aspx target_blank>Contact Us/a>/li> /ul> /div> div classcol-12 col-sm-8 footer-nav footer-nav-new mobile-100> ul> li>a hrefhttps://www.astellas.us/about/index.aspx target_blank>About Astellas/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.com/us/privacy-policy target_blank>Privacy Policy/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/footer/legal/ target_blank>Terms of Use/a>/li> li classdivider>|/li> li>a hrefhttps://www.astellas.us/about/contact/index.aspx target_blank>Contact Us/a>/li> /ul> /div> div classcol-12 col-sm-4 text-center> div classfooter-logo mobile-101 stylepadding-left: 100px;> img src/Content/img/logo--astellas--white.png altAstellas logo /> /div> div classfooter-logo mobile-100> img src/Content/img/logo--astellas--white.png altAstellas logo /> /div> /div> div classcol-12 col-sm-8 offset-sm-4 disclaimers mobile-101 foot-s st-1> p>All trademarks are the property of their respective owners. /p> p> Copyright © 2024 Astellas Pharma Inc. or its affiliates.span classmobile-break> /span>MAT-US-LEX-2023-00001 12/23 /p> p> MAT-US-LEX-2024-00005 07/24 /p> /div> div classcol-12 col-sm-8 offset-sm-4 disclaimers foot-s mobile-100 foot-align> p>All trademarks are the property of their respective owners. /p> p> Copyright © 2024 Astellas Pharma Inc. or its affiliates. /p> p> MAT-US-LEX-2023-00001 12/23 /p> p> MAT-US-LEX-2024-00005 07/24 /p> /div>/footer> /div> /div> script typetext/javascript> var confirmed localStorageconfirmed; if (!confirmed) { document.body.classList.add(roadblock); document.getElementById(roadblock).classList.add(visible); }/script> script src/bundles/jquery?v2u0aRenDpYxArEyILB59ETSCA2cfQkSMlxb6jbMBqf81>/script> script src/bundles/bootstrap?vRkJ-XGc7tgesO-7QScClyRTvQNy_Gnm3eii4FkAbu6Q1>/script> script src/bundles/fastclick?vYQVujt2zoySyZ_FxL5xnBFH013oeijgkAHrtu2n2U841>/script> script src/Content/dist/main.bundle.js typetext/javascript>/script> script> // Lets wrap everything inside a function so variables are not defined as globals (function () { // This is gonna our percent buckets ( 25%-75% ) var divisor 25; var videoTitle null; var playStatus true; var pauseStatus true; // Were going to save our players status on this object. var videos_status {}; // This is the funcion that is gonna handle the event sent by the player listeners function eventHandler(e) { //if (e.target.id.includes(dosing)) { if (e.target.parentElement.player.analytics.analytics.config.title.includes(dosing)) { videoTitle Dosing and Administration Video; } else { videoTitle Mechanism of Action Video; } switch (e.type) { // This event type is sent everytime the player updated its current time, // Were using for the % of the video played. case timeupdate: // Lets set the save the current players video time in our status object videos_statuse.target.id.current Math.round(e.target.currentTime); // We just want to send the percent events once var pct Math.floor(100 * videos_statuse.target.id.current / e.target.duration); for (var j in videos_statuse.target.id._progress_markers) { if (pct > j && j > videos_statuse.target.id.greatest_marker) { videos_statuse.target.id.greatest_marker j; } } // current bucket hasnt been already sent to GA?, lets push it to GTM if (videos_statuse.target.id.greatest_marker && !videos_statuse.target.id._progress_markersvideos_statuse.target.id.greatest_marker) { videos_statuse.target.id._progress_markersvideos_statuse.target.id.greatest_marker true; dataLayer.push({ event: video, eventCategory: HTML5 Video, eventAction: videos_statuse.target.id.greatest_marker + %, // We are using sanitizing the current video src string, and getting just the video name part eventLabel: videoTitle }); } break; // This event is fired when users click on the play button case play: if (playStatus) { dataLayer.push({ event: video, eventCategory: HTML5 Video, eventAction: Played video, eventLabel: videoTitle }); playStatus false; } else { dataLayer.push({ event: video, eventCategory: HTML5 Video, eventAction: Resumed video, eventLabel: videoTitle }); } break; // This event is fied when users click on the pause button case pause: if (pauseStatus) { dataLayer.push({ event: video, eventCategory: HTML5 Video, eventAction: Paused video, eventLabel: videoTitle, eventValue: videos_statuse.target.id.current }); pauseStatus false; } else { dataLayer.push({ event: video, eventCategory: HTML5 Video, eventAction: Resumed video, eventLabel: videoTitle }); } break; // If the user ends playing the video, an Finish video will be pushed ( This equals to % played 100 ) case ended: dataLayer.push({ event: video, eventCategory: HTML5 Video, eventAction: 100%, eventLabel: videoTitle }); break; default: break; } } // We need to configure the listeners // Lets grab all the the video objects on the current page var videos document.getElementsByTagName(video); for (var i 0; i videos.length; i++) { // In order to have some id to reference in our status object, we are adding an id to the video objects // that dont have an id attribute. var videoTagId; if (!videosi.getAttribute(id)) { // Generate a random alphanumeric string to use is as the id videoTagId html5_video_ + Math.random().toString(36).slice(2); videosi.setAttribute(id, videoTagId); }// Current video has alredy a id attribute, then lets use it img draggablefalse classemoji alt? srchttps://s.w.org/images/core/emoji/2/svg/1f642.svg> else { videoTagId videosi.getAttribute(id); } // Video Status Object declaration videos_statusvideoTagId {}; // Well save the highest percent mark played by the user in the current video. videos_statusvideoTagId.greatest_marker 0; // Lets set the progress markers, so we can know afterwards which ones have been already sent. videos_statusvideoTagId._progress_markers {}; for (j 0; j 100; j++) { videos_statusvideoTagId.progress_point divisor * Math.floor(j / divisor); videos_statusvideoTagId._progress_markersvideos_statusvideoTagId.progress_point false; } // On page DOM, all players currentTime is 0 videos_statusvideoTagId.current 0; // Now were setting the event listeners. videosi.addEventListener(play, eventHandler, false); videosi.addEventListener(pause, eventHandler, false); videosi.addEventListener(ended, eventHandler, false); videosi.addEventListener(timeupdate, eventHandler, false); videosi.addEventListener(ended, eventHandler, false); } })(); /script>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]